Hyaluronidase Access in 2025: When Regulatory Reality Undermines Clinical Safety in Aesthetic Medicine

Background: Hyaluronic acid (HA) fillers are among the most commonly performed aesthetic procedures worldwide. Hyaluronidase is the sole enzymatic antidote capable of reversing HA filler-related vascular occlusion, a rare but potentially vision- and tissue-threatening complication. Established international guidelines uniformly endorse immediate hyaluronidase availability as a non-negotiable safety requirement.Objective: This evidence-informed narrative and perspective review examines the mismatch between clinical standards mandating hyaluronidase availability and the real-world access constraints facing practitioners in 2025, with focus on the European and German regulatory environment.Methods: A review of peer-reviewed literature, clinical guidelines, regulatory documentation, and expert consensus statements was conducted. Grey-literature sources and institutional notifications are incorporated where they constitute the most current available evidence. AI-assisted language tools were used in the preparation of this manuscript for drafting and editorial refinement. All content was reviewed, verified, and approved by the authors, who take full responsibility for the accuracy and integrity of the final text.Results: Access barriers documented in official shortage registers, professional society notifications, and regulatory reports include restrictive prescription frameworks, fragmented supply chains, and regulatory classifications that do not reflect hyaluronidase’s emergency rescue function. These barriers are particularly pronounced in Germany: BfArM officially documented Hylase® Dessau shortages across 2023, and in June 2025 the DGHO notified clinicians that the manufacturer had ceased production entirely. The clinical consequence is a safety paradox: advances in filler technology have not been matched by equivalent improvements in reversal agent accessibility, with direct implications for patient safety, practitioner liability, and the reversibility principle underpinning modern aesthetic medicine.Conclusions: Regulatory frameworks governing hyaluronidase must be re-evaluated in light of its life-saving function. Targeted policy reform, structured access models, and mandatory training integration are needed to align regulatory structures with clinical standards of care.